2.49 -0.12 (-4.6%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 8.06 | 1-year : | 11.44 |
Resists | First : | 6.9 | Second : | 9.8 |
Pivot price | 2.82 ![]() |
|||
Supports | First : | 2.22 | Second : | 1.84 |
MAs | MA(5) : | 2.62 ![]() |
MA(20) : | 3.15 ![]() |
MA(100) : | 8.12 ![]() |
MA(250) : | 13.24 ![]() |
|
MACD | MACD : | -0.6 ![]() |
Signal : | -0.6 ![]() |
%K %D | K(14,3) : | 6.5 ![]() |
D(3) : | 6.3 ![]() |
RSI | RSI(14): 39.8 ![]() |
|||
52-week | High : | 22.5 | Low : | 2.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EVAX ] has closed above bottom band by 33.2%. Bollinger Bands are 45% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.8 - 2.81 | 2.81 - 2.83 |
Low: | 2.39 - 2.41 | 2.41 - 2.43 |
Close: | 2.46 - 2.49 | 2.49 - 2.52 |
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Sun, 16 Feb 2025
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Sun, 16 Feb 2025
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
Fri, 14 Feb 2025
Evaxion secures Nasdaq listing with equity boost - MSN
Fri, 14 Feb 2025
Evaxion Biotech A/S Secures Nasdaq Compliance, Extends Cash Runway to Mid-2026 - Nasdaq
Fri, 14 Feb 2025
Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination -February 14, 2025 at 08:00 am EST - Marketscreener.com
Fri, 14 Feb 2025
Financial Turnaround: Evaxion Secures Future with $17M Raise, Dodges Delisting - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 6 (M) |
Shares Float | 36 (M) |
Held by Insiders | 9.2 (%) |
Held by Institutions | 10.2 (%) |
Shares Short | 102 (K) |
Shares Short P.Month | 24 (K) |
EPS | -14 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -57.4 % |
Return on Assets (ttm) | -69.5 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0.52 |
Sales Per Share | 0.52 |
EBITDA (p.s.) | -2.38 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | -0.18 |
PEG Ratio | 0 |
Price to Book value | 249 |
Price to Sales | 4.74 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |